FDA
-
-
-
-
-
-
-
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
-
-
-
-
-
-
-
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
-
-
-
-
-
-
-
Morgan Stanley says 'buy the dip' in Disc Medicine (IRON)
-
-
-
-
-
-
-
BMO on Disc Medicine (IRON) Post Mgmt Call: 'management indicated that FDA has given no indication that the NDA review process is currently at risk'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Disc Medicine (IRON)
-
-
-
-
-
-
-
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Disc Medicine (IRON) PT Raised to $94 at Stifel
-
323,406 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

